|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM100093043 |
| 003 |
DE-627 |
| 005 |
20231222115430.0 |
| 007 |
tu |
| 008 |
231222s1999 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0334.xml
|
| 035 |
|
|
|a (DE-627)NLM100093043
|
| 035 |
|
|
|a (NLM)10075873
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Fleisher, T A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Detection of intracellular phosphorylated STAT-1 by flow cytometry
|
| 264 |
|
1 |
|c 1999
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.04.1999
|
| 500 |
|
|
|a Date Revised 21.11.2008
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We have applied flow cytometry to the investigation of interferon-gamma activation of human monocytes. This approach uses monoclonal antibodies that distinguish between the native and phosphorylated forms of STAT-1. It enables rapid and quantitative assessment of STAT-1 phosphorylation on a discrete cell basis and is both more sensitive and less time consuming than immunoblotting. Furthermore, it allows for discrimination between a mixture of cells that differ in their response to interferon-gamma. This approach should allow for the evaluation of different intracellular signaling pathways using a combination of monoclonal reagents that are specific for native and activation modified proteins. Application of this form of testing should prove valuable in screening for signaling defects in selected patients with recurrent infections. In addition, this technique should permit dissection of a full range of cellular signaling pathways at the protein level
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a DNA-Binding Proteins
|2 NLM
|
| 650 |
|
7 |
|a Phosphoproteins
|2 NLM
|
| 650 |
|
7 |
|a STAT1 Transcription Factor
|2 NLM
|
| 650 |
|
7 |
|a STAT1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Trans-Activators
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Dorman, S E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Anderson, J A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vail, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brown, M R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Holland, S M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 90(1999), 3 vom: 01. März, Seite 425-30
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:90
|g year:1999
|g number:3
|g day:01
|g month:03
|g pages:425-30
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 90
|j 1999
|e 3
|b 01
|c 03
|h 425-30
|